secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001193125-21-320242
Event type: debt
Sentiment:  neutral
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva prices $5B equivalent sustainability-linked notes; proceeds to repay debt
------------------------------------------------------------------------------

- Teva upsized and priced €1.1B 3.75% notes due 2027, €1.5B 4.375% notes due 2030, $1B 4.75% notes due 2027, and $1B 5.125% notes due 2029.
- Largest-ever sustainability-linked note offering and first by a generic medicine company; tied to access-to-medicines and GHG targets.
- Net proceeds to fund tender offer for up to $3.5B of existing senior notes maturing 2022-2024 and for general corporate purposes.
- Settlement expected November 9, 2021; notes are unsecured senior obligations guaranteed by Teva.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312521320242/0001193125-21-320242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312521320242/d599039d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-320242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer